No Data
US Stock MarketDetailed Quotes
AUPH Aurinia Pharmaceuticals
Watchlist
8.750
-0.070-0.79% Trading 12/05 10:07 ET
8.830High8.630Low236.90KVolume
8.740Open8.820Pre Close2.06MTurnover0.17%Turnover RatioLossP/E (TTM)1.26BMarket Cap12.43052wk HighLossP/E (Static)143.61MShares4.07052wk Low3.21P/B1.23BFloat Cap33.972Historical High--Dividend TTM140.72MShs Float1.000Historical Low--Div YieldTTM2.27%Amplitude8.711Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Aurinia Pharmaceuticals Company
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
Product revenue, net103.47M77.20%
License, royalty and collaboration revenue30.56M22.80%
News
Even Though Aurinia Pharmaceuticals (NASDAQ:AUPH) Has Lost US$63m Market Cap in Last 7 Days, Shareholders Are Still up 68% Over 1 Year
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio)
Aurinia Pharma Jumps Amid Takeover Speculation
Watching Aurinia Pharmaceuticals; Traders Circulating Gordon Haskett Says Gilead Could Be About To Acquire The Company
Watching Aurinia Pharmaceuticals; Traders Circulating Gordon Haskett Says Gilead Could Be About To Acquire The Company
Comments
If the company can sustain its revenue growth, the share price may further increase. The company's performance appears to have improved recently, as the one-year total shareholder return is better than the five-year total shareholder return.
Even Though Aurinia Pharmaceuticals (NASDAQ:AUPH) Has Lost US$63m Market Cap in Last 7 Days, Shareholders Are Still up 68% Over 1 Year
$Aurinia Pharmaceuticals(AUPH.US$ I'm watching this one
2
Analysts predict Aurinia Pharmaceuticals will breakeven before running out of cash. Its growth trajectory and ability to raise funds mitigates the risk of cash burn.
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--